Gold prices slid below $4,000/oz amid profit-taking on Gaza ceasefire
Investing.com - H.C. Wainwright has reiterated its Buy rating and $20.00 price target on Actuate Therapeutics (NASDAQ:ACTU), representing a significant upside from the current trading price of $7.09. According to InvestingPro data, analyst targets for the stock range from $20 to $35.
The company announced on September 22 that it amended the Investigational New Drug (IND) application for its drug elraglusib to include positive clinical data from the ongoing Phase 2 study, Actuate-1801 Part 3B.
This clinical data was previously presented at the 2025 annual meeting of the American Society of Clinical Oncology (ASCO), according to the company’s announcement.
Actuate Therapeutics also stated that its recent equity offering generated gross proceeds of $17.25 million, which the company expects will fund operations through its planned regulatory submissions.
The company anticipates completing applications to both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in early 2026.
In other recent news, Actuate Therapeutics has announced positive results from its Phase 2 trial for its drug candidate elraglusib, which showed a significant improvement in survival rates for metastatic pancreatic cancer patients. The trial demonstrated a 37% reduction in the risk of death and doubled the 12-month survival rate when elraglusib was combined with standard chemotherapy. Additionally, Actuate Therapeutics has raised $17.25 million through a public offering of common stock, which included the full exercise of the underwriter’s over-allotment option. Prior to this, the company had priced an underwritten public offering, expecting to raise approximately $15 million in gross proceeds. In another development, B.Riley initiated coverage of Actuate Therapeutics with a Buy rating, setting a price target of $20.00, and highlighting the potential of elraglusib in treating pancreatic ductal adenocarcinoma. These developments underscore Actuate’s ongoing efforts in advancing cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.